NO151288B - ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE INDOLOKINOLIZINDINS - Google Patents
ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE INDOLOKINOLIZINDINS Download PDFInfo
- Publication number
- NO151288B NO151288B NO783958A NO783958A NO151288B NO 151288 B NO151288 B NO 151288B NO 783958 A NO783958 A NO 783958A NO 783958 A NO783958 A NO 783958A NO 151288 B NO151288 B NO 151288B
- Authority
- NO
- Norway
- Prior art keywords
- preparation
- product
- ethyl
- therapeutically active
- indolokinolizindins
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 3
- 238000002360 preparation method Methods 0.000 title description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- -1 trimethoxy-substituted phenyl Chemical group 0.000 claims description 5
- OURDZMSSMGUMKR-UHFFFAOYSA-N 1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizine Chemical class C1=CC=C2C(CCN3CCCCC33)=C3NC2=C1 OURDZMSSMGUMKR-UHFFFAOYSA-N 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 32
- 239000000047 product Substances 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 5
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- HHJCTMQTCFULDG-UHFFFAOYSA-N 1-ethyl-3,4,6,7,12,12b-hexahydro-2h-indolo[2,3-a]quinolizine-1-carbonitrile Chemical compound C1=CC=C2C(CCN3CCCC(C43)(CC)C#N)=C4NC2=C1 HHJCTMQTCFULDG-UHFFFAOYSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- SKPGDHHYCYKJIK-UHFFFAOYSA-N 5-chloro-2-cyano-2-ethylpentanoyl chloride Chemical compound CCC(C(Cl)=O)(C#N)CCCCl SKPGDHHYCYKJIK-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000004452 microanalysis Methods 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
- DIOKNYUWXBKNEH-UHFFFAOYSA-N (1-ethyl-3,4,6,7,12,12b-hexahydro-2H-indolo[2,3-a]quinolizin-1-yl)methanamine Chemical compound C(C)C1(CCCN2CCC3=C(C12)NC1=CC=CC=C13)CN DIOKNYUWXBKNEH-UHFFFAOYSA-N 0.000 description 1
- FQMWCEMJFGFVRN-UHFFFAOYSA-N 2,3,4,6,7,8,9,9a-octahydro-1h-quinolizine;perchloric acid Chemical compound [O-]Cl(=O)(=O)=O.C1CCCC2CCCC[NH+]21 FQMWCEMJFGFVRN-UHFFFAOYSA-N 0.000 description 1
- BUHYMJLFRZAFBF-UHFFFAOYSA-N 3,4,5-trimethoxybenzoyl chloride Chemical compound COC1=CC(C(Cl)=O)=CC(OC)=C1OC BUHYMJLFRZAFBF-UHFFFAOYSA-N 0.000 description 1
- QVFZNYXMJKUGKE-UHFFFAOYSA-N 5-chloro-2-cyano-2-ethyl-n-[2-(1h-indol-3-yl)ethyl]pentanamide Chemical compound C1=CC=C2C(CCNC(=O)C(CCCCl)(C#N)CC)=CNC2=C1 QVFZNYXMJKUGKE-UHFFFAOYSA-N 0.000 description 1
- 229910014813 CaC2 Inorganic materials 0.000 description 1
- WZNQLNOSNCIDDT-UHFFFAOYSA-N Cl.COC=1C=C(C(=O)NCC2(CCCN3CCC4=C(C23)NC2=CC=CC=C24)CC)C=C(C1OC)OC Chemical compound Cl.COC=1C=C(C(=O)NCC2(CCCN3CCC4=C(C23)NC2=CC=CC=C24)CC)C=C(C1OC)OC WZNQLNOSNCIDDT-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- MHCFAGZWMAWTNR-UHFFFAOYSA-M lithium perchlorate Chemical compound [Li+].[O-]Cl(=O)(=O)=O MHCFAGZWMAWTNR-UHFFFAOYSA-M 0.000 description 1
- 229910001486 lithium perchlorate Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- LJPZHJUSICYOIX-UHFFFAOYSA-N quinolizidine Chemical compound C1CCCC2CCCCN21 LJPZHJUSICYOIX-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Description
Denne oppfinnelse angår fremstilling av nye indolo-(2,3-a)kinolizidiner. This invention relates to the preparation of new indolo-(2,3-a)quinolizidines.
De nye indolo(2,3-a)kinolizidiner som fremstilles i henhold til oppfinnelsen, har de generelle formler (I) og (II) The new indolo(2,3-a)quinolizidines produced according to the invention have the general formulas (I) and (II)
hvor R betyr where R means
hvor R' er where R' is
- et til C,. alkoksyradikal; eller - one to C,. alkoxy radical; or
- et trimetoksy-substituert fenylradikal; - a trimethoxy-substituted phenyl radical;
Ifølge oppfinnelsen fremstilles også syreaddisjonssaltene av de ovenstående forbindelser. According to the invention, the acid addition salts of the above compounds are also produced.
Forbindelsene som fremstilles i henhold til oppfinnelsen er særlig av interesse på grunn av sin virkning på blodsirkulasjonen i hjernen. En eller flere av forbindelsene fremstilt i henhold til oppfinnelsen kan innarbeides i terapeutiske preparater sammen med et terapeutisk godtagbart fortynningsmiddel eller bæremiddel. The compounds produced according to the invention are of particular interest because of their effect on blood circulation in the brain. One or more of the compounds produced according to the invention can be incorporated into therapeutic preparations together with a therapeutically acceptable diluent or carrier.
De ovenstående forbindelser fremstilles i henhold til oppfinnelsen ved at en tilsvarende forbindelse hvor R betyr -CI^-NI^» kondenseres med en forbindelse med formelen R'COHal, hvor R' er som innledningsvis angitt, og Hal er halogen. Utgangsmaterialet kan fremstilles ved at 2-aminoetyl-3-indol kondenseres med l-klor-4-cyano-4-klorkarbonyl-heksan, for å danne det tilsvarende amid; amidet underkastes sterkt basiske betingelser for å eliminere HC1 og frembringe ringdannelse ved nitrogenatomet på 3-indol-substituenten; kinolizidin-ringdannelse av produktet frem-bringes ved å behandle det med et dehydratiseringsmiddel fulgt av et perkloratsalt; det resulterende kinolizidiniumperklorat hydro-generes for å frembringe den tilsvarende 1-etyl-l-cyano-indolo-(2,3-a)-kinolizidin-isomerblanding, og isomerene separeres. Aminometyl-utgangsmaterialet oppnås derefter. The above compounds are prepared in accordance with the invention by condensing a corresponding compound where R means -CI^-NI^» with a compound of the formula R'COHal, where R' is as stated at the outset, and Hal is halogen. The starting material can be prepared by condensing 2-aminoethyl-3-indole with 1-chloro-4-cyano-4-chlorocarbonyl-hexane to form the corresponding amide; the amide is subjected to strongly basic conditions to eliminate HCl and produce ring formation at the nitrogen atom of the 3-indole substituent; quinolizidine cyclization of the product is produced by treating it with a dehydrating agent followed by a perchlorate salt; the resulting quinolizidinium perchlorate is hydrogenated to produce the corresponding 1-ethyl-1-cyano-indolo-(2,3-a)-quinolizidine isomeric mixture, and the isomers are separated. The aminomethyl starting material is then obtained.
I de følgende skjemaer betegner: In the following forms denotes:
Typiske reaksjonsbetingelser for hvert reaksjonstrinn er som illustrert i de følgende eksempler. Andre betingelser for ut-førelse av de samme omdannelser vil være åpenbare for fagfolk. Typical reaction conditions for each reaction step are as illustrated in the following examples. Other conditions for carrying out the same conversions will be obvious to those skilled in the art.
De følgende eksempler skal tjene til å illustrere oppfinnelsen Eksempel 1 The following examples shall serve to illustrate the invention Example 1
(a) Fremstilling av 3-[ 2'-(2"-cyano-2"-etyl-5"-kl or-valeroylamino)- etyl]- indol (a) Preparation of 3-[2'-(2"-cyano-2"-ethyl-5"-chloro-valeroylamino)-ethyl]-indole
I en 1 liters kolbe ble anbragt 31 g (0,19 4 mol) tryptamin, 500 ml diklormetan og 20 g (0,198 mol) trietylamin. Blandingen ble avkjølt til 0°C over is, og det ble tilsatt 31 g (0.19 4 mol) of tryptamine, 500 ml of dichloromethane and 20 g (0.198 mol) of triethylamine were placed in a 1 liter flask. The mixture was cooled to 0°C over ice and it was added
40 g (0,192 mol) 2-cyano-2-ety1-5-klor-valeroylklorid oppløst i 150 ml metyldiklorid. Efter 2 timer ved romtemperatur ble blandingen vasket med vann, derefter med 10%ig saltsyre og derefter med 10%ig natriumhydroksyd. Den ble tørret, og oppløsningsmidlet ble fjernet ved avdampning. Produktet, omkrystallisert fra isopropyleter/petroleter, smeltet ved 120°C (utbytte 40 g). Analyseresultatene er som følger: 40 g (0.192 mol) of 2-cyano-2-ethyl-5-chloro-valeroyl chloride dissolved in 150 ml of methyl dichloride. After 2 hours at room temperature, the mixture was washed with water, then with 10% hydrochloric acid and then with 10% sodium hydroxide. It was dried and the solvent was removed by evaporation. The product, recrystallized from isopropyl ether/petroleum ether, melted at 120°C (yield 40 g). The analysis results are as follows:
Beregnet for C^H^t^ClO: C 65,0, H 6,64, N 12,65% Calculated for C^H^t^ClO: C 65.0, H 6.64, N 12.65%
Funnet: C 64,03, H.6,78, N 12,60%. Found: C 64.03, H.6.78, N 12.60%.
(b) Fremstilling av 1-[ ( 2'- indol- 3"- yl- etyl)- 3- etyl- 3- cyano]-2- piperidon (b) Preparation of 1-[(2'-indol-3"-yl-ethyl)-3-ethyl-3-cyano]-2- piperidone
I en 1 liter rundbunnet kolbe ble anbragt 22 g 22 g were placed in a 1 liter round-bottomed flask
(0,0665 mol) av produktet fra trinn (a) ovenfor, 200 ml tetrahydrofuran og 300 ml t-butanol. Blandingen ble avkjølt til 0°C over is, og det ble tilsatt, i små mengder, 8,5 g (0,076 mol) kalium-tert.butoksyd. Efter 2 timer ved romtemperatur ble blandingen redusert i volum og hydrolysert. Den organiske fase ble ekstrahert med metylendiklorid, vasket med vann, tørret og oppløsningsmidlet ble fjernet ved inndampning. Det ønskede produkt, omkrystallisert fra etanol/eter 50/50 smeltet ved 180°C (utbytte 15 g, 80%). Analyseresultatene er som følger: (0.0665 mol) of the product from step (a) above, 200 ml of tetrahydrofuran and 300 ml of t-butanol. The mixture was cooled to 0°C over ice and 8.5 g (0.076 mol) potassium tert-butoxide was added in small amounts. After 2 hours at room temperature, the mixture was reduced in volume and hydrolysed. The organic phase was extracted with methylene dichloride, washed with water, dried and the solvent was removed by evaporation. The desired product, recrystallized from ethanol/ether 50/50 melted at 180°C (yield 15 g, 80%). The analysis results are as follows:
Beregnet for ClgH23N30: C 73,2, H 7,1 N 14,2% Calculated for ClgH23N30: C 73.2, H 7.1 N 14.2%
Funnet: C 72,46 H 7,15, N 14,01% (c) Fremstilling av l- etyl- l- cyano- 5, 12b- didehydro- indolo-( 2, 3- a) kinolizidinium- perklorat Found: C 72.46 H 7.15, N 14.01% (c) Preparation of l-ethyl-l-cyano-5,12b-didehydro-indolo-(2,3-a)quinolizidinium-perchlorate
I en 1 liters kolbe ble anbragt under omrøring 50 g (0,169 mol) av produktet fra trinn (b) ovenfor og 700 ml fosforyl-klorid. Efter oppvarmning under tilbakeløpskjøling i 20 timer 50 g (0.169 mol) of the product from step (b) above and 700 ml of phosphoryl chloride were placed in a 1 liter flask with stirring. After heating under reflux cooling for 20 hours
ble rekasjonsblandingen konsentrert og ekstrahert 2 eller 3 ganger med 500 ml metylendiklorid som derefter ble fjernet ved avdampning. Produktet ble tatt opp i 300 ml metylendiklorid og avkjølt over is, og 300 ml av en oppløsning av litiumperklorat (1 mol) ble tilsatt the reaction mixture was concentrated and extracted 2 or 3 times with 500 ml of methylene dichloride which was then removed by evaporation. The product was taken up in 300 ml of methylene dichloride and cooled over ice, and 300 ml of a solution of lithium perchlorate (1 mol) was added
under kraftig omrøring. Det ble dannet et gult bunnfall som efter oinkrystal lise ring fra metanol smeltet ved 260°C (utbytte 44 g, 70%). Analyseresultatene er som følger: under vigorous stirring. A yellow precipitate was formed which, after recrystallization from methanol, melted at 260°C (yield 44 g, 70%). The analysis results are as follows:
IR 3400 cm<-1> NH indol IR 3400 cm<-1> NH indole
2260 cm"<1> C=N 2260 cm"<1> C=N
1620 cm"<1> C=N<+ >(d) Fremstilling av 1- etyl- 1- cyano- indolo( 2, 3- a) kinolizidin 1620 cm"<1> C=N<+ >(d) Preparation of 1- ethyl- 1- cyano- indolo( 2, 3- a) quinolizidine
( 12b- H, l- C^H^ trans- isomer) (12b- H, l- C^H^ trans isomer)
I en i 1 liters rundbunnet kolbe ble anbragt 200 ml metanol, 100 ml metylendiklorid og 13,5 g (0,036 mol) av perkloratproduktet fra trinn (c) ovenfor. Kolben ble avkjølt til ca. 5°C, og 5 g natriumborhydrat ble tilsatt i små mengder. Oppløsningen ble derefter omrørt i 2 timer ved romtemperatur, konsentrert, vasket med vann og ekstrahert med metylendiklorid. Efter tørring og fjernelse av oppløsningsmidlet fikk man 8 g gule krystaller, 200 ml of methanol, 100 ml of methylene dichloride and 13.5 g (0.036 mol) of the perchlorate product from step (c) above were placed in a 1 liter round bottom flask. The flask was cooled to approx. 5°C, and 5 g of sodium borohydrate were added in small amounts. The solution was then stirred for 2 hours at room temperature, concentrated, washed with water and extracted with methylene dichloride. After drying and removal of the solvent, 8 g of yellow crystals were obtained,
som efter omkrystallisering fra isopropyleter smeltet ved 160°C (utbytte 80%). Analyseresultatene er som følger: IR 3420 cm"1 ) which after recrystallization from isopropyl ether melted at 160°C (yield 80%). The analysis results are as follows: IR 3420 cm"1 )
3440 cm"<1> ) 3440 cm"<1> )
2760 cm"<1>' ) 2760 cm"<1>' )
2 800 cm ) NH- og Bohlmann-bånd 2,800 cm ) NH and Bohlmann bands
2250 cm"<1> CN 2250 cm"<1> CN
NMR (dimetylsulfoksyd, dg, 80 MHz) 6 NMR (dimethyl sulfoxide, dg, 80 MHz) 6
0,86, 3H i(t) (CH ) 0.86, 3H in (t) (CH )
3,77, 1H (s) (H ved Cn ) 3.77, 1H (s) (H at Cn )
— 9a — 9a
9,66, 1H (s) (NH) 9.66, 1H (s) (NH)
Beregnet for c1sH21N3: C 77'7' K 7. 2, N 15,2% Calculated for c1sH21N3: C 77'7' K 7.2, N 15.2%
Funnet: C 77,55, H 7,32, N 15,10%. Found: C 77.55, H 7.32, N 15.10%.
(e) Fremstilling av 1- etyl- l- cyano- indolo( 2, 3- a) kinolizidin (e) Preparation of 1-ethyl-1-cyano-indolo(2,3-a)quinolizidine
( 12b- H, 1- C2H5 cis- isomer) ( 12b- H, 1- C2H5 cis- isomer)
I en 1 liters kolbe ble anbragt 19 g av perkloratproduktet fra trinn (c) ovenfor, 300 ml 95%ig etanol og 40 g sinkpulver. Derefter ble 100 ml konsentrert saltsyre tilsatt. Svakt tilbakeløp kunne iakttas under tilsetning av syren. Blandingen fikk stå 19 g of the perchlorate product from step (c) above, 300 ml of 95% ethanol and 40 g of zinc powder were placed in a 1 liter flask. Then 100 ml of concentrated hydrochloric acid was added. Weak reflux could be observed during addition of the acid. The mixture was allowed to stand
ved romtemperatur i 10 timer. Den ble derefter konsentrert, vasket med vann og ekstrahert med metylendiklorid. Den ble gjort alkalisk med natriumhydroksyd og filtrert gjennom "Celite". at room temperature for 10 hours. It was then concentrated, washed with water and extracted with methylene dichloride. It was made alkaline with sodium hydroxide and filtered through Celite.
Efter dekantering, tørring og avdampning av oppløsningsmidlene fikk man 6 g av et produkt, uoppløselig i eter, med smeltepunkt 250°C. Analyseresultatene er som følger: After decantation, drying and evaporation of the solvents, 6 g of a product, insoluble in ether, with a melting point of 250°C were obtained. The analysis results are as follows:
IR 3410 cm"<1> (NH) IR 3410 cm"<1> (NH)
2260 cm"<1> (CN) 2260 cm"<1> (CN)
Beregnet for <C>18H21<N>3<*1/>4H20: C 76'5' H 7'60' N 14,85% Calculated for <C>18H21<N>3<*1/>4H20: C 76'5' H 7'60' N 14.85%
Funnet: C 76,59, H 7,80, N 14,55%. Found: C 76.59, H 7.80, N 14.55%.
Eterekstraktene ble konsentrert for å gi 4 g (totalt utbytte 71,5%) av cis-isomeren av det samme produkt som trinn (d) ovenfor. The ether extracts were concentrated to give 4 g (total yield 71.5%) of the cis isomer of the same product as step (d) above.
NMR (dimetylsulfoksyd d,, 80 MH_) 6: NMR (dimethylsulfoxide d,, 80 MH_) 6:
o Land L
1,05, 3H (t) (CH3) 1.05, 3H (t) (CH3)
3,45, 1H (s) (H ved CQ ) 3.45, 1H (s) (H at CQ )
10,32, 1H (s) (NH) 10.32, 1H (s) (NH)
(f) Fremstilling av 1- etyl- l- aminometyl- indolo( 2, 3- a)-kinolizidin ( 12b- H, 1- C,,H5 trans- isomer II) (f) Preparation of 1-ethyl-1-aminomethyl-indolo(2,3-a)-quinolizidine (12b-H,1-C,,H5 trans-isomer II)
I en 1 liters kolbe ble anbragt 4 g litiumaluminium-hydrid og 400 ml tørr eter. Kolben ble avkjølt til en temperatur mellom 0 og 5°C, og det ble tilsatt, i små mengder, 8,9 g av produktet fra trinn (d) ovenfor. Efter at kolben hadde fått stå 4 g of lithium aluminum hydride and 400 ml of dry ether were placed in a 1 liter flask. The flask was cooled to a temperature between 0 and 5°C and 8.9 g of the product from step (d) above was added, in small portions. After the flask had been allowed to stand
i 1 time ved romtemperatur, ble 60 ml tørr tetrahydrofuran tilsatt. Blandingen ble oppvarmet i 2 timer under tilbakeløpskjøling. Efter avkjølingen ble det tilsatt dråpevis 40 ml vann fulgt av 200 ml metylendiklorid. Blandingen ble omrørt i 15 minutter. Efter filtrering over "Celite", tørring og konsentrering av filtratet fikk man 7,2 g hvite krystaller som efter omkrystallisering fra eter smeltet ved 175°C (80% utbytte). for 1 hour at room temperature, 60 ml of dry tetrahydrofuran was added. The mixture was heated for 2 hours under reflux. After cooling, 40 ml of water was added dropwise, followed by 200 ml of methylene dichloride. The mixture was stirred for 15 minutes. After filtration over "Celite", drying and concentration of the filtrate, 7.2 g of white crystals were obtained which after recrystallization from ether melted at 175°C (80% yield).
Analyseresultatene er som følger: The analysis results are as follows:
IR 3280, 3190 cm"<1> NH--1 IR 3280, 3190 cm"<1> NH--1
3350 cm NH indol 3350 cm NH indole
CN-toppen ved ca. 2250 cm 1 var fraværende. The CN peak at approx. 2250 cm 1 was absent.
Beregnet for C^H^: C 76,4, H 8,85, N 14,8% Calculated for C^H^: C 76.4, H 8.85, N 14.8%
Funnet: C 75,85, H 8,90, N 15,52%. Found: C 75.85, H 8.90, N 15.52%.
g) 1- etoksykarbonylaminometyl- l- etyl- indolo( 2, 3- a) kinolizidin-hydroklorid ( 12b- H, 1- C^H^ trans- isomer II) g) 1- ethoxycarbonylaminomethyl- 1- ethyl- indolo( 2, 3- a) quinolizidine hydrochloride ( 12b- H, 1- C^H^ trans-isomer II)
Til' en oppløsning av 2 g (0,00705 mol) av trans-produktet II fra (f) i 20 ml dimetoksyetan, avkjølt til 0°C, ble satt alternerende for å holde pH basisk, porsjoner av: 800 mg etylklorformiat i oppløsning i 5 ml dimetoksyetan, og 750 mg natriumkarbonat i oppløsning i 5 ml vann. To a solution of 2 g (0.00705 mol) of the trans-product II from (f) in 20 ml of dimethoxyethane, cooled to 0°C, were added alternately to keep the pH basic, portions of: 800 mg of ethyl chloroformate in solution in 5 ml of dimethoxyethane, and 750 mg of sodium carbonate in solution in 5 ml of water.
Efter at reaksjonsblandingen hadde fått stå i 3 timer ved omgivelsestemperatur ble produktet ekstrahert med diklormetan, diklormetanekstrakten ble vasket med vann, tørret og inndampet til tørrhet. Produktet ble omkrystallisert fra etanol. After the reaction mixture had been allowed to stand for 3 hours at ambient temperature, the product was extracted with dichloromethane, the dichloromethane extract was washed with water, dried and evaporated to dryness. The product was recrystallized from ethanol.
Vekt: 2 g, utbytte: 80%, Sm.p.: 140°C. Weight: 2 g, yield: 80%, Melting point: 140°C.
Resultatene av mikroanalyse er som følger: Beregnet for c2iH29<N>3°2<:> C 71'0' H 8'17' N H/8% Funnet: C 70,94, H 8,16, N 11,54%. The results of microanalysis are as follows: Calculated for c2iH29<N>3°2<:> C 71'0' H 8'17' N H/8% Found: C 70.94, H 8.16, N 11.54% .
Hydrokloridsaltet ble dannet av de ovenstående 2 g produkt ved tilsetning av 4N HC1 i 20 ml etanol. The hydrochloride salt was formed from the above 2 g of product by the addition of 4N HCl in 20 ml of ethanol.
Vekt: 2 g, utbytte: 90%, sm.p.: 260°C. Weight: 2 g, yield: 90%, m.p.: 260°C.
Eksempel 2 Example 2
1-( 3', 4', 5'- trimetoksybenzoylaminometyl)- 1- etyl- indolo-( 2 , 3- a) - kinolizidin- hydroklorid ( 12b- H, l- C^H^ trans- isomer II) 1-(3',4',5'-trimethoxybenzoylaminomethyl)-1-ethyl-indolo-(2,3-a)-quinolizidine hydrochloride (12b-H,l-C^H^ trans-isomer II)
Inn i en trehalset kolbe med volum på 250 ml utstyrt Into a three-necked flask with a volume of 250 ml equipped
med en rører, en CaC^-felle, et termometer og en dryppetrakt ble innført 2,85 g av transproduktet II fra eksempel 2(f), 1,1 g trietylamin og 50 ml diklormetan. with a stirrer, a CaC₂ trap, a thermometer and a dropping funnel, 2.85 g of the transproduct II from example 2(f), 1.1 g of triethylamine and 50 ml of dichloromethane were introduced.
Blandingen ble omrørt og avkjølt til 0,2°C. Ved denne temperatur ble det langsomt tilsatt 2,31 g 3,4,5-trimetoksybenzoyl-klorid i 15 ml diklormetan. Tilsetningen fant sted over en periode på 15 til 20 minutter, hvorefter reaksjonsblandingen ble omrørt i 1 time ved 0°C og derefter i 15 timer ved romtemperatur. The mixture was stirred and cooled to 0.2°C. At this temperature, 2.31 g of 3,4,5-trimethoxybenzoyl chloride in 15 ml of dichloromethane were added slowly. The addition took place over a period of 15 to 20 minutes, after which the reaction mixture was stirred for 1 hour at 0°C and then for 15 hours at room temperature.
Reaksjonsblandingen ble derefter vasket flere ganger med vann, derefter med 10%ig vandig natriumhydroksyd og derefter igjen med vann. Den ble tørret over natriumsulfat og konsentrert for å danne en ikke-krystallinsk masse med tekstur som marengs og med smeltepunkt nær 100°C. The reaction mixture was then washed several times with water, then with 10% aqueous sodium hydroxide and then again with water. It was dried over sodium sulfate and concentrated to form a non-crystalline mass with a meringue texture and melting point near 100°C.
TLC: metylenklorid/metanol: 90/10, Rf = 8/10 TLC: methylene chloride/methanol: 90/10, Rf = 8/10
IR 3230 cm"1 NH IR 3230 cm"1 NH
3190 cm"<1> NH 3190 cm"<1> NH
2 750 og 2800 cm"<1>Bohlmann bånd 2,750 and 2,800 cm"<1>Bohlmann band
1640 cm <1> C=0 amid 1640 cm <1> C=0 amide
Mengde base med HC104: 97% Amount of base with HC104: 97%
Mengden av base bestemt ved en anhydro-titrimetrisk metode under anvendelse av perklorsyre i iseddik. The amount of base determined by an anhydro-titrimetric method using perchloric acid in glacial acetic acid.
For å fremstille hydrokloridsaltet ble det ovenstående produkt oppløst i en 1:1 blanding av diisopropyleter og isopropanol, og 4N saltsyre ble tilsatt. Hydrokloridsaltet krystalliserte i varm tilstand og ble filtrert varmt og vasket med etanol for å gi 4,5 g (88% utbytte) av produktet. To prepare the hydrochloride salt, the above product was dissolved in a 1:1 mixture of diisopropyl ether and isopropanol, and 4N hydrochloric acid was added. The hydrochloride salt crystallized while hot and was filtered hot and washed with ethanol to give 4.5 g (88% yield) of the product.
TLC: metylenklorid/metanol: 90/10, Rf = 8/10 TLC: methylene chloride/methanol: 90/10, Rf = 8/10
Sm.p. : 210°C, Koffler) Sm.p. : 210°C, Koffler)
Mengde av hydroklorid: 100% (1 funksjon). Amount of hydrochloride: 100% (1 function).
Mikroanalyse ga de følgende resultater: Microanalysis gave the following results:
Beregnet for C28<H>35N3°4'HC1: C 65'45' H 7'00' N 8,18% Calculated for C28<H>35N3°4'HC1: C 65'45' H 7'00' N 8.18%
Funnet: C 64,34, H 7,17, N 8,11% Found: C 64.34, H 7.17, N 8.11%
C 64,15, H 7,16, N 7,96%. C 64.15, H 7.16, N 7.96%.
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB4920177 | 1977-11-25 |
Publications (3)
Publication Number | Publication Date |
---|---|
NO783958L NO783958L (en) | 1979-05-28 |
NO151288B true NO151288B (en) | 1984-12-03 |
NO151288C NO151288C (en) | 1985-03-13 |
Family
ID=10451538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO783958A NO151288C (en) | 1977-11-25 | 1978-11-23 | ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE INDOLOKINOLIZINDINS |
Country Status (28)
Country | Link |
---|---|
JP (1) | JPS6147838B2 (en) |
AR (1) | AR218514A1 (en) |
AT (1) | AT372384B (en) |
AU (1) | AU529108B2 (en) |
BE (1) | BE872134A (en) |
CA (1) | CA1100959A (en) |
CH (1) | CH641181A5 (en) |
DE (1) | DE2851028A1 (en) |
DK (1) | DK154430C (en) |
EG (1) | EG13683A (en) |
ES (1) | ES475328A1 (en) |
FI (1) | FI64372C (en) |
FR (2) | FR2423492A1 (en) |
HK (1) | HK60884A (en) |
IE (1) | IE47518B1 (en) |
IN (1) | IN151146B (en) |
IT (1) | IT1160263B (en) |
LU (1) | LU80576A1 (en) |
MX (1) | MX5529E (en) |
MY (1) | MY8500029A (en) |
NL (1) | NL7811562A (en) |
NO (1) | NO151288C (en) |
NZ (1) | NZ188974A (en) |
PT (1) | PT68825A (en) |
SE (2) | SE431650B (en) |
SG (1) | SG61182G (en) |
WO (1) | WO1979000319A1 (en) |
ZA (1) | ZA786426B (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3175900D1 (en) * | 1981-11-18 | 1987-03-12 | Thal Claude | Indoloquinolizine derivatives, process for their preparation and their therapeutic use |
FR2529552B1 (en) * | 1982-07-05 | 1985-09-27 | Centre Nat Rech Scient | NOVEL PROCESS FOR THE PREPARATION OF VINDOLINE SYNTHESIS INTERMEDIATES AND SYNTHESIS INTERMEDIATES |
HU191454B (en) * | 1984-10-05 | 1987-02-27 | Richter Gedeon Vegyeszeti Gyar Rt.,Hu | Process for producing amides of oktahydro-indolo/2,3-a/quinolyzin-1-yl-alkanecarboxylic acids and pharmaceutically acceptable acid additional salts thereof |
HU194220B (en) * | 1985-04-19 | 1988-01-28 | Richter Gedeon Vegyeszet | Process for production of derivatives of 1,12 b disubstituated-octahydro-indolo /2,3-a/ quinolisine and medical compounds containing thereof |
HU195214B (en) * | 1985-04-19 | 1988-04-28 | Richter Gedeon Vegyeszet | Process for producing 12b-substituted-1-(hydroxymethyl)-octahydro-indolo /2,3-a/ quinolizine derivatives and pharmaceutical preparations comprising these compounds |
FI95572C (en) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Process for the preparation of a medicament useful as a piperidine derivative or its pharmaceutical salt |
DK0704439T3 (en) * | 1993-06-18 | 2001-10-08 | Fujisawa Pharmaceutical Co | Hitherto unknown intermediate for synthetic application and process for the preparation of aminopiperazine derivatives |
FR2713644B1 (en) * | 1993-12-14 | 1996-02-09 | Adir | New analogs of eburnane, process for their preparation and pharmaceutical compositions containing them. |
FR2713643B1 (en) * | 1993-12-14 | 1996-06-07 | Adir | New analogs of eburnane, process for their preparation and pharmaceutical compositions containing them. |
US7798176B2 (en) † | 2002-06-24 | 2010-09-21 | Saint-Gobain Isover | Insulating panel for supply duct |
FR2911141B1 (en) * | 2007-01-05 | 2009-02-20 | Servier Lab | NOVEL TRIAZABENZO [A] NAPHTHO [2,1,8-CDE] AZULENE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
FR2911143A1 (en) * | 2007-01-05 | 2008-07-11 | Servier Lab | Use of neuroprotective compounds to prepare medicaments for treating neurodegenerative diseases |
FR2911142A1 (en) * | 2007-01-05 | 2008-07-11 | Servier Lab | New amino-pyrroloindole and amino-pyridazinoindole derivatives, are tyrosine hydroxylase inducers, useful e.g. for treating anxiety, depression or memory loss |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU167366B (en) * | 1972-09-06 | 1975-09-27 | ||
BE802387A (en) * | 1973-07-16 | 1973-11-16 | Omnium Chimique Sa | PROCESS FOR PREPARING VINCAMONE AND EPI-21 VINCAMONE FROM TABERSONIN AND NEW INDOLIC DERIVATIVES. |
HU169916B (en) * | 1974-09-27 | 1977-02-28 | ||
HU171165B (en) * | 1974-11-26 | 1977-11-28 | Richter Gedeon Vegyeszet | Process for producing oktahydro-indolo-bracket-2,3-a-bracket closed-quinolizine derivatives |
FR2315277A1 (en) * | 1975-06-25 | 1977-01-21 | Anvar | NEW PENTACYCLIC DERIVATIVES, THEIR PREPARATION AND THE COMPOSITIONS CONTAINING THEM |
-
1978
- 1978-11-15 ZA ZA00786426A patent/ZA786426B/en unknown
- 1978-11-20 BE BE191824A patent/BE872134A/en not_active IP Right Cessation
- 1978-11-22 NZ NZ188974A patent/NZ188974A/en unknown
- 1978-11-23 FI FI783581A patent/FI64372C/en not_active IP Right Cessation
- 1978-11-23 AU AU41874/78A patent/AU529108B2/en not_active Expired
- 1978-11-23 PT PT68825A patent/PT68825A/en unknown
- 1978-11-23 AR AR274552A patent/AR218514A1/en active
- 1978-11-23 ES ES475328A patent/ES475328A1/en not_active Expired
- 1978-11-23 NO NO783958A patent/NO151288C/en unknown
- 1978-11-23 AT AT0837478A patent/AT372384B/en active
- 1978-11-24 JP JP54500118A patent/JPS6147838B2/ja not_active Expired
- 1978-11-24 IT IT30171/78A patent/IT1160263B/en active
- 1978-11-24 FR FR7833175A patent/FR2423492A1/en active Granted
- 1978-11-24 WO PCT/FR1978/000043 patent/WO1979000319A1/en unknown
- 1978-11-24 IE IE2328/78A patent/IE47518B1/en unknown
- 1978-11-24 MX MX787557U patent/MX5529E/en unknown
- 1978-11-24 DK DK524978A patent/DK154430C/en not_active IP Right Cessation
- 1978-11-24 FR FR7833176A patent/FR2409755A1/en active Granted
- 1978-11-24 LU LU80576A patent/LU80576A1/en unknown
- 1978-11-24 DE DE19782851028 patent/DE2851028A1/en active Granted
- 1978-11-24 NL NL7811562A patent/NL7811562A/en not_active Application Discontinuation
- 1978-11-24 CH CH683579A patent/CH641181A5/en not_active IP Right Cessation
- 1978-11-24 CA CA316,809A patent/CA1100959A/en not_active Expired
- 1978-11-24 IN IN851/DEL/78A patent/IN151146B/en unknown
- 1978-11-25 EG EG669/78A patent/EG13683A/en active
-
1979
- 1979-07-23 SE SE7906287A patent/SE431650B/en not_active IP Right Cessation
-
1980
- 1980-11-07 SE SE8007845A patent/SE435622B/en not_active IP Right Cessation
-
1982
- 1982-12-03 SG SG611/82A patent/SG61182G/en unknown
-
1984
- 1984-08-02 HK HK608/84A patent/HK60884A/en unknown
-
1985
- 1985-12-30 MY MY29/85A patent/MY8500029A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO151288B (en) | ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE INDOLOKINOLIZINDINS | |
JPH01238571A (en) | Pyrrolopyridine-acetonitriles and acetamides, and use thereof as herbicide | |
SE452459B (en) | INDOL-5-METANESULPHONAMIDE, A PHARMACEUTICAL COMPOSITION AND A PROCEDURE FOR PREPARING THE SUBSTANCE | |
NO312669B1 (en) | Non-peptide bombesin receptor antagonists, their use and pharmaceutical preparations containing such | |
DK157995B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF INCIDENTAL DERIVATIVES | |
Hermkens et al. | Syntheses of 1, 3-disubstituted N-oxy-β-carbolines by the Pictet-Spengler reactions of N-oxy-tryptophan and-tryptamine derivatives | |
NO174773B (en) | Process for Preparation of Quinolone Carboxylic Acids | |
DK170044B1 (en) | Process for Preparation of N-Substituted Dihydrolyseric Acid Derivatives | |
US4614806A (en) | Process for the asymmetric synthesis of chiral indoline-2-carboxylic acids | |
US4353911A (en) | Indolo(2,3-a)quinolizidines, useful in increasing femoral and vertebral blood flow | |
Kim | Synthesis of 1, 2, 3, 4, 8, 9, 10, 11‐octahydro‐[1, 4] diazepino [6, 5, 4‐jk] earbazole and related compounds | |
NO178373B (en) | Process for the preparation of therapeutically active ergoline derivatives | |
KR900004002B1 (en) | 5-thioxo-2-imidazolinyl benzoic acids | |
US4584385A (en) | Antibacterial 2-amino-oxazolinones and process therefor | |
JPS6148839B2 (en) | ||
SU591150A3 (en) | Method of preparing nitroimidazolyltriazolopyridazine derivatives or salts thereof | |
DK169970B1 (en) | Intermediates for use in the preparation of pyrimido [4,5-g] quinoline derivatives or salts thereof | |
Brandao et al. | A novel way of synthesis of l, 3, 5-trisubstituted-2-thioxoimidazolidinones | |
US4550165A (en) | Process for producing 1,2,5,6-tetrahydro-4H-pyrrolo-[3,2,1-ij]-quinolin-4-one | |
HU194164B (en) | Process for production of 1,2-dihydroxi-3-//2-indolil-1,1-dialkyl-ethil/-amin/-prophanes | |
US4595755A (en) | 5-halo-1,2,3-(1,2-dihydropyrrolo)-4-quinolones | |
US4062891A (en) | N-formyl-2,3,5,6-dibenzobicyclo[5.1.0]octan-4-methylamine | |
CA2028953A1 (en) | Process for the preparation of quinazoline derivatives | |
US4644081A (en) | Process for the asymmetric synthesis of chiral indoline-2-carboxylic acids | |
NO146237B (en) | PROCEDURE FOR THE PREPARATION OF THE THERAPEUTIC ACTIVE 4- (2-HYDROXY-3-ISOPROPYLAMINO-PROPOxy) INDOL |